PMID- 29042751
OWN - NLM
STAT- MEDLINE
DCOM- 20180723
LR  - 20221207
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 11
DP  - 2017
TI  - Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: 
      evidence to date.
PG  - 2905-2919
LID - 10.2147/DDDT.S114932 [doi]
AB  - Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic 
      strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an 
      insulin-independent mechanism (glycosuria), they reduce glucose toxicity and 
      improve insulin sensitivity and beta-cell function. The promising results obtained 
      in clinical trials show that SGLT2 significantly improves glycemic control and 
      provides greater cardiovascular protection, combined with a reduction in body 
      weight and blood pressure (BP). This review focuses on ertugliflozin, a new, 
      highly selective, and reversible SGLT2 inhibitor. Clinical trials published to 
      date show that ertugliflozin, both as a monotherapy and as an add-on to oral 
      antidiabetic agents, is safe and effective in reducing glycosylated hemoglobin 
      (HbA1c), body weight, and BP in T2DM patients.
FAU - Cinti, Francesca
AU  - Cinti F
AD  - Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario 
      A Gemelli, Universita Cattolica del Sacro Cuore, Rome, Italy.
FAU - Moffa, Simona
AU  - Moffa S
AD  - Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario 
      A Gemelli, Universita Cattolica del Sacro Cuore, Rome, Italy.
FAU - Impronta, Flavia
AU  - Impronta F
AD  - Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario 
      A Gemelli, Universita Cattolica del Sacro Cuore, Rome, Italy.
FAU - Cefalo, Chiara Ma
AU  - Cefalo CM
AD  - Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario 
      A Gemelli, Universita Cattolica del Sacro Cuore, Rome, Italy.
FAU - Sun, Vinsin A
AU  - Sun VA
AD  - Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario 
      A Gemelli, Universita Cattolica del Sacro Cuore, Rome, Italy.
FAU - Sorice, Gian Pio
AU  - Sorice GP
AD  - Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario 
      A Gemelli, Universita Cattolica del Sacro Cuore, Rome, Italy.
FAU - Mezza, Teresa
AU  - Mezza T
AD  - Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario 
      A Gemelli, Universita Cattolica del Sacro Cuore, Rome, Italy.
FAU - Giaccari, Andrea
AU  - Giaccari A
AD  - Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario 
      A Gemelli, Universita Cattolica del Sacro Cuore, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171003
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Blood Glucose)
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 6C282481IP (ertugliflozin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Blood Glucose/drug effects
MH  - Blood Pressure/drug effects
MH  - Body Weight/drug effects
MH  - Bridged Bicyclo Compounds, Heterocyclic/administration & 
      dosage/pharmacology/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Insulin/metabolism
MH  - Insulin-Secreting Cells/metabolism
MH  - Sodium-Glucose Transporter 2
MH  - Sodium-Glucose Transporter 2 Inhibitors
PMC - PMC5633300
OTO - NOTNLM
OT  - antidiabetic drugs
OT  - glycemic control
OT  - glycosylated hemoglobin
OT  - precision medicine
OT  - sodium-glucose cotransporter 2 inhibitors
OT  - type 1 diabetes mellitus
OT  - type 2 diabetes mellitus
OT  - weight reduction
COIS- Disclosure AG has received consultancy fees from Boehringer Ingelheim, MSD, 
      Sanofi, Eli Lilly, Takeda, and Astra Zeneca. The sponsors were not directly 
      involved in the design and conduct of the paper, the collection, management, 
      analysis, and interpretation of the data, or the preparation, review, or approval 
      of the manuscript. The authors report no other conflicts of interest in this 
      work.
EDAT- 2017/10/19 06:00
MHDA- 2018/07/24 06:00
PMCR- 2017/10/03
CRDT- 2017/10/19 06:00
PHST- 2017/10/19 06:00 [entrez]
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2018/07/24 06:00 [medline]
PHST- 2017/10/03 00:00 [pmc-release]
AID - dddt-11-2905 [pii]
AID - 10.2147/DDDT.S114932 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2017 Oct 3;11:2905-2919. doi: 10.2147/DDDT.S114932. 
      eCollection 2017.